These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15721381)

  • 1. Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice.
    Ahmad A; Wang YF; Ahmad I
    Methods Enzymol; 2005; 391():176-85. PubMed ID: 15721381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
    Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
    Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Release profile of compound liposomes entrapped with vincristine sulfate and mitoxantrone chlorhydric acid in vitro and their distribution in mice].
    Chen T; Hou SX; Wang YY; Zhang WS; Chen DH
    Yao Xue Xue Bao; 2006 Dec; 41(12):1170-5. PubMed ID: 17290615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation.
    Johnson JL; Ahmad A; Khan S; Wang YF; Abu-Qare AW; Ayoub JE; Zhang A; Ahmad I
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jan; 799(1):149-55. PubMed ID: 14659447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.
    Cordeiro Pedrosa LR; van Tellingen O; Soullié T; Seynhaeve AL; Eggermont AM; Ten Hagen TL; Verheij M; Koning GA
    Eur J Pharm Biopharm; 2015 Aug; 94():207-19. PubMed ID: 25982691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
    Schwendener RA; Fiebig HH; Berger MR; Berger DP
    Cancer Chemother Pharmacol; 1991; 27(6):429-39. PubMed ID: 2013113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide.
    Zhang L; Ren Y; Wang Y; He Y; Feng W; Song C
    Int J Nanomedicine; 2018; 13():1097-1105. PubMed ID: 29520138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Preparation of liposome entrapped vincristine sulfate and mitoxantrone chlorhydric acid].
    Chen T; Hou SX; Wang YY; Zhang WS; Shi BQ
    Zhongguo Zhong Yao Za Zhi; 2007 Apr; 32(8):678-81. PubMed ID: 17608217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice.
    Reszka R; Beck P; Fichtner I; Hentschel M; Richter J; Kreuter J
    J Pharmacol Exp Ther; 1997 Jan; 280(1):232-7. PubMed ID: 8996201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer.
    Rentsch KM; Schwendener RA; Pestalozzi BC; Sauter C; Wunderli-Allenspach H; Hänseler E
    Eur J Clin Pharmacol; 1998 Mar; 54(1):83-9. PubMed ID: 9591936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic effect and toxicity of compound vincristine liposome on breast cancer in nude mice].
    Chen T; Hou S; Wang Y; Zhang W; Liao H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):127-9, 143. PubMed ID: 19334570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases.
    Lu B; Xiong SB; Yang H; Yin XD; Chao RB
    Eur J Pharm Sci; 2006 May; 28(1-2):86-95. PubMed ID: 16472996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
    Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced dose-limiting toxicity of intraperitoneal mitoxantrone chemotherapy using cardiolipin-based anionic liposomes.
    Chang RS; Kim J; Lee HY; Han SE; Na J; Kim K; Kwon IC; Kim YB; Oh YK
    Nanomedicine; 2010 Dec; 6(6):769-76. PubMed ID: 20570638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPLC analysis of mitoxantrone in mouse plasma and tissues: application in a pharmacokinetic study.
    An G; Morris ME
    J Pharm Biomed Anal; 2010 Feb; 51(3):750-3. PubMed ID: 19850431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone-loaded BSA nanospheres and chitosan nanospheres for local injection against breast cancer and its lymph node metastases. II: Tissue distribution and pharmacodynamics.
    Lu B; Xiong SB; Yang H; Yin XD; Zhao RB
    Int J Pharm; 2006 Jan; 307(2):175-81. PubMed ID: 16314056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice.
    Genne P; Olsson NO; Gutierrez G; Duchamp O; Chauffert B
    Anticancer Drug Des; 1994 Apr; 9(2):73-84. PubMed ID: 8166930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
    Lim HJ; Masin D; Madden TD; Bally MB
    J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.
    Rentsch KM; Horber DH; Schwendener RA; Wunderli-Allenspach H; Hänseler E
    Br J Cancer; 1997; 75(7):986-92. PubMed ID: 9083333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.
    de Vries NA; Ouwehand M; Buckle T; Beijnen JH; van Tellingen O
    Biomed Chromatogr; 2007 Nov; 21(11):1191-200. PubMed ID: 17582233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.